Experienced in Hairy Cell Leukemia (HCL)

Dr. Christopher D. Fletcher

Internal Medicine
4201 Murphy Rd Ste B, 
Nashville, TN 
Experienced in Hairy Cell Leukemia (HCL)
4201 Murphy Rd Ste B, 
Nashville, TN 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Christopher Fletcher is a primary care provider, practicing in Internal Medicine in Nashville, Tennessee. Dr. Fletcher is rated as an Experienced provider by MediFind in the treatment of Hairy Cell Leukemia (HCL). His top areas of expertise are Solitary Fibrous Tumor, Small Lymphocytic Lymphoma (SLL), Chronic B-Cell Leukemia (CBCL), and Chronic Lymphocytic Leukemia (CLL).

His clinical research consists of co-authoring 55 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Hairy Cell Leukemia (HCL).

Specialties
Internal Medicine
Licenses
Internal Medicine in TN
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

4201 Murphy Rd Ste B, Nashville, TN 37209

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase I Trial of the Combination of Lenalidomide and Blinatumomab in Patients With Relapsed or Refractory Non-Hodgkins Lymphoma (NHL)
A Phase I Trial of the Combination of Lenalidomide and Blinatumomab in Patients With Relapsed or Refractory Non-Hodgkins Lymphoma (NHL)
Enrollment Status: Completed
Publish Date: November 26, 2025
Intervention Type: Biological, Drug
Study Drugs: Blinatumomab, Lenalidomide
Study Phase: Phase 1
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Drug, Biological, Other
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
Phase II Study of Venetoclax (ABT-199/GDC-0199) in Combination With Obinutuzumab and Bendamustine in Patients With High Tumor Burden Follicular Lymphoma as Front Line Therapy
Phase II Study of Venetoclax (ABT-199/GDC-0199) in Combination With Obinutuzumab and Bendamustine in Patients With High Tumor Burden Follicular Lymphoma as Front Line Therapy
Enrollment Status: Completed
Publish Date: May 23, 2025
Intervention Type: Drug
Study Drug: Venetoclax
Study Phase: Phase 2
A Phase II Study of Split-Dose R-CHOP in Older Adults With Diffuse Large B-cell Lymphoma
A Phase II Study of Split-Dose R-CHOP in Older Adults With Diffuse Large B-cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: March 26, 2025
Intervention Type: Biological, Drug
Study Drugs: Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Pegfilgrastim
Study Phase: Phase 2
A Phase I/II Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma
A Phase I/II Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma
Enrollment Status: Completed
Publish Date: January 18, 2024
Intervention Type: Drug
Study Drugs: Ixazomib, Ibrutinib
Study Phase: Phase 1/Phase 2
View 4 Less Clinical Trials

55 Total Publications

Genetic correlates of malignancy in TFE3-rearranged PEComa: a series of 14 cases.
Genetic correlates of malignancy in TFE3-rearranged PEComa: a series of 14 cases.
Journal: Histopathology
Published: March 19, 2025
Similar Doctors
Experienced in Hairy Cell Leukemia (HCL)
Dr. Richa C. Misra
Internal Medicine
Experienced in Hairy Cell Leukemia (HCL)
Dr. Richa C. Misra
Internal Medicine
1310 24th Ave S, 
Nashville, TN 
 (8.6 miles away)
800-228-4973
Languages Spoken:
English

Richa Misra is a primary care provider, practicing in Internal Medicine in Nashville, Tennessee. Dr. Misra is rated as an Experienced provider by MediFind in the treatment of Hairy Cell Leukemia (HCL). Her top areas of expertise are Typhoid Fever, Salmonella Enterocolitis, Anthrax Infection, and Scrofula.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Fletcher's expertise for a condition
ConditionClose
        View All 14 Experienced Conditions
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile